Why is "Remdesivir" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-26 21:09:03
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Remdesivir | Definition, Uses, & Side Effects - Britannica
-
Remdesivir in COVID-19: pros and cons - Frontiers
-
remdesivir covid-19 cost savings ASHP Midyear - Infectious Disease Special Edition
-
Remdesivir Criteria Save $500K-Plus Without Affecting Outcomes - Pharmacy Practice News
-
Combination Therapy With Ensitrelvir and Remdesivir Versus Antiviral Monotherapy in Patients Receiving Anti-CD20 Monoclonal Antibody Therapy: A Retrospective Cohort Study - Cureus
-
Molecular basis of SARS-CoV-2 proofreading enzyme–mediated resistance to remdesivir - PNAS
-
Remdesivir Tied to Lower Mortality in COVID-19 Patients With Liver or Kidney Disease - Pharmacy Practice News
-
UGM Doctoral Student Examines Effectiveness of Remdesivir in COVID-19 Patients - Universitas Gadjah Mada
-
The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load - Nature
-
3 EPIDEMIOLOGY OF COVID-19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCY - Wiley Online Library
-
Remdesivir for the Treatment of Covid-19 — Final Report - The New England Journal of Medicine
-
FDA Approves First Treatment for COVID-19 - fda.gov
-
Molecular basis of SARS-CoV-2 proofreading enzyme–mediated resistance to remdesivir - PNAS
-
Final report confirms remdesivir benefits for COVID-19 - National Institutes of Health (.gov)
-
The ‘very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug - Science | AAAS
-
COVID patients who don't receive remdesivir not more likely to die, data suggest - CIDRAP
-
Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19 - Nature
-
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients - The New England Journal of Medicine
-
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus - Nature
-
The Goldilocks Time for Remdesivir — Is Any Indication Just Right? - The New England Journal of Medicine
-
Why remdesivir, a highly effective COVID treatment, is a last resort for providers - NPR
-
COVID-19 Treatments: What We Know So Far - Yale Medicine
-
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets - Nature
-
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir - Nature
-
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis - Nature
-
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial - Nature
-
Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients - Nature
-
How remdesivir works, and why it's not the ultimate coronavirus killer - Stanford Medicine
-
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 - Nature
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 - The New England Journal of Medicine
-
The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis - Nature
-
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - The Lancet
-
Remdesivir for Hospitalized Patients with COVID-19 - Ontario COVID-19 Science Advisory Table
-
Real-world evidence shows remdesivir tied to less death in hospitalized COVID patients - CIDRAP
-
Trump Is Taking Remdesivir. Here's How It Works To Control The Coronavirus - NPR
-
New study supports remdesivir as COVID-19 treatment - Vanderbilt Health News
-
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery - National Institutes of Health (.gov)
-
Remdesivir Priced At More Than $3,100 For A Course Of Treatment - NPR
-
Remdesivir increases mtDNA copy number causing mild alterations to oxidative phosphorylation | Scientific Reports - Nature
-
Remdesivir Shows Significant Survival Benefit Among Inpatients With COVID-19 - Vaccine Advisor
-
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
-
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice - Science | AAAS
-
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report - Nature
-
The effect of remdesivir on mortality and the outcome of patients with COVID-19 in intensive care unit: A case–control study - Wiley Online Library
-
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir - Science | AAAS
-
What factors allowed for timely pediatric approvals of remdesivir for treatment of COVID-19? - AAP
-
SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care - Nature
-
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis - Nature
-
Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS - Frontiers
-
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study - Frontiers
-
Clinical pharmacodynamics of obeldesivir versus remdesivir - ASM Journals
-
Study Supports Use of Remdesivir for COVID-19 Patients on Low-Flow Oxygen or No Oxygen - Johns Hopkins Medicine
-
Covid-19 study details benefits of treatment with remdesivir, and also its limitations - statnews.com
-
Early results show benefit of remdesivir for COVID-19 - National Institutes of Health (.gov)
-
US secures world stock of key Covid-19 drug remdesivir - The Guardian
-
The Effects of Remdesivir on Mortality, Ventilation in Patients With COVID-19 - Pulmonology Advisor
-
Remdesivir: What to know about the first drug approved to treat COVID-19 - Boston Children's Answers
-
Remdesivir’s hefty price tag ignores NIH investment in its creation - statnews.com
-
Remdesivir tied to 54% lower risk of death among hospitalized COVID patients - CIDRAP
-
Repetitive stability study of remdesivir/cyclodextrin complex on the international space station - Nature
-
Baricitinib plus remdesivir shows promise for treating COVID-19 - National Institutes of Health (.gov)
-
Scientists Discover How Remdesivir Works to Inhibit Coronavirus - The University of Texas at Austin
-
Remdesivir and molnupiravir had comparable efficacy in lung transplant recipients with mild-to-moderate COVID-19: a single center experience - Frontiers
-
WHO advises against use of remdesivir for treating COVID-19 - Al Jazeera
-
Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction - Nature
-
The Strange Story Of Remdesivir, A Covid Drug That Doesn’t Work - Forbes
-
WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients - statnews.com
-
How Feds Decide On Remdesivir Shipments To States Remains Mysterious - NPR
-
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells - Nature
-
From Houston to Miami, hospitals running short of remdesivir for Covid-19 patients - statnews.com
-
Trump gets dexamethasone, remdesivir for COVID-19 - UCHealth
-
Gilead Sciences Sets US Price for COVID-19 Drug at $2340 to $3120 Based on Insurance - AJMC
-
How Could the Price of Remdesivir Impact Medicare Spending for COVID-19 Patients? - KFF
-
New Study Looks at Drug Exposures of COVID-19 Therapy for Pregnant People - CU Anschutz newsroom
-
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report - Nature
-
Remdesivir Did Not Improve Mortality at Hospitals, Prolonged Stays - Contagion Live
-
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge - Nature
-
Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting - Nature
-
Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial (Published 2020) - The New York Times
-
Gilead's remdesivir reduces COVID-19 mortality risk- data - Reuters
-
Gilead’s Covid-19 Drug Is Mediocre. It Will Be a Blockbuster Anyway. (Published 2020) - The New York Times
-
COVID treatment studied by VUMC gains FDA approval - Vanderbilt Health News
-
Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study - Nature
-
Remdesivir plus dexamethasone tied to lower COVID death rate - CIDRAP
-
The US has bought most of the world’s remdesivir. Here’s what it means for the rest of us - The Conversation
-
How Remdesivir Moved From Back Shelf to Best Hope for Treating COVID-19 - Time Magazine
-
Covid-19 and remdesivir: rethinking how we measure a drug’s ‘value’ - statnews.com
-
Federal Scientists Finally Publish Remdesivir Data (Published 2020) - The New York Times
-
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial - The Lancet
-
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections - Nature
-
Dexamethasone, remdesivir, Regeneron: Trump's Covid treatment explained - BBC
-
Remdesivir shouldn't be used on hospitalized Covid-19 patients, WHO advises - NBC News
-
Here Are Remdesivir’s Possible Side Effects (Intravenous Injection) - GoodRx
-
Remdesivir, the First Coronavirus Drug, Gets a Price Tag (Published 2020) - The New York Times
-
What is Remdesivir & How Is It Used For COVID-19? - Hackensack Meridian Health
-
Remdesivir gets FDA approval for COVID-19 treatment - CNET
-
Hepatitis C Drugs Combined with Remdesivir Show Strong Effectiveness Against COVID-19 - Mount Sinai
-
Remdesivir tied to lower COVID death rates in hospital patients receiving oxygen - CIDRAP
-
Use of Dexamethasone, Remdesivir Against COVID-19 Varied Widely Across U.S. Health Systems - Johns Hopkins Bloomberg School of Public Health
-
The FDA Has Approved Remdesivir for the Treatment of COVID-19 - Lupus Foundation of America
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.